Zobrazeno 1 - 10 of 30 pro vyhledávání: '"Robert M. O'Bryan"'
1
Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base
Autor: Robert B. Livingston, David Gandara, Kathy S. Albain, John Crowley, Robert M. O'Bryan, Brian Griffin, Daniel D. Von Hoff, Laura Hutchins
Publikováno v: Cancer. 72:1184-1191
Background. Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of tes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f8e65dac9b6cbc625531ce92db6005d
https://doi.org/10.1002/1097-0142(19930815)72:4<1184::aid-cncr2820720409>3.0.co
Zobrazit plný text záznamu
3
Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients
Autor: Frank R. Lewis, Eleanor M. Walker, Vic Velanovich, Wanda Szymanski, John J. Ferrara, Molly Gabel, Thomas J. Doyle, Robert M. O'Bryan
Publikováno v: Journal of the American College of Surgeons. 194(1)
Background: Ageism has been suggested as a cause for the undertreatment of elderly breast cancer patients. The purpose of this study was to determine the rate and causes of elderly patients not receiving standard therapy. Study Design: A random sampl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d2c14cb58db00dc900a6652ce513dad
https://pubmed.ncbi.nlm.nih.gov/11800343
Zobrazit plný text záznamu
6
Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study
Autor: Ronald L. Stephens, Stanley P. Balcerzak, Jess Frank, Robert M. O'Bryan, Clarence B. Vaughn, Howard S. Levin, J. J. Costanzi, Montague Lane, Charles A. Coltman
Publikováno v: Cancer. 53:406-410
Over a 24-month period, the Southwest Oncology Group (SWOG) conducted a randomized prospective chemotherapeutic trial in 158 patients with advanced prostatic cancer. Patients were initially randomized to receive either a combination of Adriamycin and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b34241768178afffb260ec00af7cfcc7
https://doi.org/10.1002/1097-0142(19840201)53:3<406::aid-cncr2820530307>3.0.co
Zobrazit plný text záznamu
7
VP-16 + adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A southwest oncology group study
Autor: J. Benjamin Green, Stephanie Green, P. N. Grozea, Robert M. O'Bryan, Clarence B. Vaughn, Noboru Oishi, William S. Fletcher, Melvin L. Reed, Barbara Metch
Publikováno v: Medical and Pediatric Oncology. 16:312-319
One hundred twenty-two patients with advanced adenocarcinoma of the breast were randomized to receive adriamycin (AD) alone or a combination of VP-16 plus lower dose adriamycin (VAD). The patients were stratified to good and poor risk. The starting d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12542ad52140ef0e8b681c066076089
https://doi.org/10.1002/mpo.2950160505
Zobrazit plný text záznamu
8
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma a southwest oncology group study
Autor: Muhyi Al-Sarraf, Sarah A. Taylor, William S. Fletcher, Harmon J. Eyre, Stanley P. Balcerzak, Robert M. O'Bryan, John J. Costanzi, Jess Frank
Publikováno v: Cancer. 53:833-836
Two hundred-eighty patients were randomized to receive either BCNU, hydroxyurea and imidazole carboxamide (BHD), BHD plus levamisole, or high-dose DTIC plus actinomycin D. There was no difference in response rate in the three groups (24%, 25% and 22%
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dec781d92e3c193d2ca5946f720a9412
https://doi.org/10.1002/1097-0142(19840215)53:4<833::aid-cncr2820530402>3.0.co
Zobrazit plný text záznamu
9
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery
Autor: Saul E. Rivkin, Bruce McDonalds, James R. Eltringham, Robert M. O'Bryan, Harmon J. Eyre, Joseph M. Quagliana, Jess Frank
Publikováno v: Journal of Neuro-Oncology. 1:171-177
One hundred and fifteen eligible patients with histologically verified malignant gliomas (astrocytoma grade III–IV) were randomized to receive either radiotherapy 6 000 rads/7 week plus CCNU 130 mg/ M2 every 6 weeks (treatment 1) or radiotherapy 60
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed0e0874c2aa6fd3c427887c700e701
https://doi.org/10.1007/bf00165600
Zobrazit plný text záznamu
10
Does thyroid substance improve response of breast cancer to surgical castration?
Autor: Samuel G. Taylor, Rita M. Kelley, Gilbert S. Gordan, Robert G. Ravdin, Robert M. O'Bryan, Albert Segaloff
Publikováno v: Cancer. 33:1082-1085
Under the aegis of the Cooperative Breast Cancer Group, 13 principal investigators studied a total of 218 female patients with metastatic carcinoma of the breast. All patients either were menstruating actively or were less than 1 year past the menopa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2efaef61f73717d0411c57e0d7d4ec9
https://doi.org/10.1002/1097-0142(197404)33:4<1082::aid-cncr2820330428>3.0.co
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje